A nemia is one of the most commonly encountered abnormal laboratory findings in intensive care unit (ICU) patients, and many ICU patients will receive a blood transfusion during their ICU stay. However, determinants of exactly which patients to transfuse remain poorly defined and have been the subject of considerable debate in recent years. Concerns have been raised regarding the safety of blood transfusions, in part due to fears of transfusion-related transferal of infectious diseases such as human immunodeficiency virus (HIV), and more recently bovine spongiform encephalitis, and in part related to observations that blood transfusions may increase the risk of infections, by complex effects collectively grouped under "transfusion-related immunomodulation." As a result of these concerns and several studies suggesting better or similar outcomes with lower transfusion triggers (1) or worse outcomes in transfused patients (2, 3) , there has been a general decrease in the transfusion threshold from the 10 g/dL hemoglobin concentration widely used in the past, with many physicians now waiting till the hemoglobin concentration approaches 7 g/dL before transfusing (4, 5) .
In this article, we focus on some of the key studies providing insight into current transfusion practices and fuelling the current debate on the optimum transfusion trigger.
Epidemiology and Etiology of Anemia in the ICU. Critically ill patients often develop anemia during their ICU stay. The prospective, multiple-center, observational cohort CRIT study in the United States, which included 4,892 ICU patients, reported that almost two thirds of patients had a hemoglobin concentration Ͻ12 g/dL (3) . The etiology of the anemia is multifactorial (Table 1) . Although primary blood loss from trauma, surgery, gastrointestinal bleeding, and so on represents a key cause of anemia in the ICU patient, hemoglobin concentrations decrease even in nonbleeding critically ill patients (6) . Nguyen Ba et al. (6) studied the time-course of hemoglobin concentrations in 91 nonbleeding critically ill patients and reported that hemoglobin concentrations fell by 0.52 Ϯ 0.69 g/dL/ day for the whole population, with a more marked fall over the first 3 days than for subsequent days (0.66 Ϯ 0.84 vs. 0.12 Ϯ 0.29 g/dL/day, p Ͻ .01, Fig. 1 ). Interestingly, the pattern was slightly different in patients with sepsis compared with nonseptic patients, with a greater daily decline in hemoglobin concentrations in septic patients (0.68 Ϯ 0.66 vs. 0.44 Ϯ 0.70 g/dL/day, p ϭ .13); in addition, in nonseptic patients the decline in hemoglobin concentrations stabilized after 3 days whereas in septic patients it continued.
The pathogenesis of this decrease in hemoglobin concentrations in nonbleeding ICU patients is likely a combination of losses from phlebotomy and minor procedures, reduced red cell production, and maybe increased red cell destruction.
Repeated blood sampling can cause significant blood loss (7) (8) (9) . Corwin at al (9) . reported that phlebotomy accounted for almost 30% of the total blood transfused in 142 ICU patients, with increased phlebotomy blood losses in patients who were transfused. In the Anemia and Blood Transfusion in Critical Care (ABC) study, the average daily phlebotomy volume was 41 mL/day (2). In the study by Nguyen Ba et al. (6) , phlebotomy losses amounted to 40.3 mL/day, with slightly more blood samples and larger volumes (49.0 Ϯ 11.3 vs. 36.7 Ϯ 14.9 mL/day, p ϭ .04) taken in septic than nonseptic patients, which may have accounted in part for the greater daily decline in hemoglobin concentrations in these patients. An abnormal erythropoietin response to blood loss, in part related to the effects of inflammatory mediators on the production of erythropoietin and the erythropoietin receptor (10, 11) and by induction of apoptosis on erythroblasts (12), also contributes to the anemia in ICU patients (13) (14) (15) . Nutritional, including iron, deficiencies may contribute to the decreased production (16) . Vasodilation secondary to the inflammatory response may lead to an increased blood volume, which may contribute to decrease hematocrit despite a constant red cell mass. Increased red blood cell (RBC) uptake by the reticuloendothelial system due to alterations of the RBC membrane (17) could also contribute to the development of anemia in critically ill patients.
Epidemiology of Transfusion in the ICU. With the high incidence of anemia, many ICU patients will receive a blood transfusion at some point during their ICU stay, with recent quoted figures ranging from 20% to 53% (Table 2) . Indeed, several large multiple-center studies have assessed the epidemiology of blood transfusion in ICU patients over the last decade or so. In a Canadian study involving 5,298 ICU patients, Hebert et al. (18) reported that 25% of patients received an RBC transfusion during their ICU stay. In the United Kingdom, 53% of 1,247 critically ill patients received an RBC transfusion during their ICU stay (19) . The ABC study, conducted across 146 western European countries and involving 3,534 patients, noted that 37% of patients received a blood transfusion at some point during their ICU stay (2) . This number increased with increasing length of ICU stay (25% for patients who stayed Յ2 days, 56% in those staying Ͼ2 days, and 73% in those with stays Ͼ7 days). In the CRIT study, 44% of patients received one or more RBC units while in the ICU (3) . The recent Sepsis Occurrence in Acutely ill Patients (SOAP) study (20) , which included 3,147 patients from 198 European ICUs, reported that 33% of the patients received a blood transfusion during their stay.
Benefits and Risks of Transfusion Versus Anemia. Blood transfusions are given with the aim of improving oxygen delivery and hence limiting tissue hypoxia and damage. However, although oxygen delivery is improved, there is not necessarily a concomitant increase in tissue oxygenation or oxygen utilization (21) (22) (23) . In addition, risks are associated with blood transfusions including transmission of microorganisms; transfusion-related immunomodulation, which may increase the risk of infections; transfusion-related acute lung injury; and human errors (wrong type and cross-match, incorrect patient identification, etc.), which can cause hemolytic reactions.
In 1999, Hebert et al. (1) published the results of a randomized controlled study that compared the outcomes of critically ill patients managed with a liberal blood transfusion strategy (hemoglobin concentration kept at Ͼ10 g/dL as was general practice at the time) with a restrictive transfusion practice (hemoglobin concentration maintained at Ͼ7 g/dL). Patients in the liberal group received a mean of 5.6 units of RBCs, compared with 2.6 units in the restrictive group (p Ͻ .01). ICU and hospital mortality rates were lower in the restrictive group, but the differences were only significant for hospital mortality (22 vs. 28%, p ϭ .05). In the subgroups of patients with lower Acute Physiology and Chronic Health Evaluation II scores (Ͻ20) and younger age (Ͻ55 yrs), mortality rates were notably lower in the restrictive group than the liberal group. The authors concluded that "hemoglobin concentrations should be maintained between 7.0 and 9.0 g per deciliter" (1) . Indeed, this study provided the kick-start to a complete rethink of transfusion strategies in the ICU, further fuelled by data from observational studies that suggested worse outcomes in patients who received blood transfusions (2, 3). The ABC study (2) reported higher ICU (19 vs. 10%, p Ͻ .001) and overall (29 vs. 15%, p Ͻ .001) mortality rates in patients who had received a blood transfusion than in those who had not. Additionally, in matched patients in a propensity analysis, the 28-day mortality rate was 22.7% among patients with transfusions and 17.1% among those without (p ϭ .02). The CRIT study showed that the number of RBC transfusions a patient received during the study was independently associated with longer ICU and hospital lengths of stay and an increase in mortality (3) .
Although blood transfusions clearly carry risks, anemia can also be associated with worse outcomes. Animal data suggest that acute hemodilution to low hemoglobin levels is well tolerated, and in healthy human volunteers acute isovolemic reduction of blood hemoglobin concentration to 5 g/dL produced no evidence of inadequate systemic oxygenation (24) , but side effects such as arrhythmia (25) were observed. However, although healthy individuals maintain oxygen consumption by identical increases in cardiac index and oxygen extraction ratio during isovolemic hemodilution, in critically ill patients, the relationship between cardiac index and oxygen extraction may be different (26) , and results from studies in healthy volunteers are unlikely to be applicable to the majority of ICU patients. Ethically it is difficult to allow patients to bleed without offering transfusion, and much of our understanding of this field has come from studies in patients who decline blood transfusions (usually for religious reasons) or from statistical analyses of large databases. In 1,958 Jehovah's Witness patients undergoing surgery, the mortality rate was 1.3% in patients with a preoperative hemoglobin of Ն12 g/dL and 33.3% in patients with a preoperative hemoglobin Ͻ6 g/dL. The increase in the risk of death associated with a low preoperative hemoglobin was more pronounced in patients with cardiovascular disease (27) . In a retrospective study of 2,083 patients who declined RBC transfusion for religious reasons, the odds of death in patients with a postoperative hemoglobin level of Յ8 g/dL increased 2.5 times for each gram decrease in hemoglobin level after adjusting for age, cardiovascular disease, and Acute Physiology and Chronic Health Evaluation II score (28) . In an observational study of 4,470 critically ill patients, patients with cardiac disease and hemoglobin concentrations Ͻ9.5 g/dL also had a trend toward an increased mortality rate (55% vs. 42%, p ϭ .09) compared with anemic patients with noncardiovascular diagnoses (29). Habib et al. (30) noted that increased hemodilution severity during cardiopulmonary bypass was associated with worse perioperative vital organ dysfunction/ morbidity and increased resource use, as well as greater short-and intermediateterm mortality. In the CRIT study, a baseline hemoglobin concentration Ͻ9 g/dL was a predictor of increased mortality and length of stay (3) .
The Transfusion Dilemma. With the ongoing debate regarding the benefits and risks of blood transfusions, it is important that each patient is assessed individually to determine his or her tolerance to anemia and need for transfusion. However, how can such patients be assessed? Clinical examination combined with background data including current diagnosis and comorbid conditions will help determine the need for transfusion. Hemoglobin concentration would be an easy variable and, indeed, has for years been the guiding factor for the "transfusion trigger," but the optimal hemoglobin concentration varies considerably from one patient to the next according to multiple factors including age, preexisting chronic diseases (especially coronary artery disease), present diagnosis, and underlying cause of the anemia. As such, using a single hemoglobin level below which all patients should be transfused, or even a scale of values for specific groups of patients, is too inflexible. The "critical hemoglobin," that is, the hemoglobin level below which oxygen delivery is compromised, would be a more reliable trigger, but how can this be measured? Currently, we have only surrogate measures of tissue oxygenation, including mixed venous oxygen saturation and blood lactate levels, and even if we had an effective means of detecting tissue hypoxia, are interventions such as blood transfusion indicated once hypoxia has already developed?
So we return to the hemoglobin concentration as our guide to transfusion; but at what hemoglobin level should we transfuse? The study by Hebert et al. (1) demonstrated that critically ill patients could be successfully managed with hemoglobin concentrations between 7 and 9 g/dL, with the possible exception of patients with acute myocardial infarcts and unstable angina (31) . Current recommendations for the management of patients with severe sepsis support a transfusion trigger of 7 g/dL (32) . In addition, studies in human volunteers have shown that isovolemic hemodilution to a hemoglobin of Յ5 g/dL does not result in biochemical evidence of anaerobic metabolism (24) , and studies in Jehovah's Witness patients have shown that survival is possible at low hemoglobin concentrations; one case study reported survival after a decrease in hemoglobin concentration to just 1.8 g/dL (33) . However, such cases are the exception and no one would suggest that all critically ill patients be allowed to reach such degrees of anemia.
Reevaluating the Transfusion Trigger. Interestingly, just as the intensive care world had begun to get used to the idea that smaller may be better in terms of hemoglobin concentrations, the SOAP study, evaluating 3,147 patients in 198 ICUs across Europe in May 2002, reported that, unlike the earlier ABC (2) and CRIT (3) studies, blood transfusion was not associated with increased mortality in multivariate analysis or by propensity case matching (20) . The ABC and SOAP studies were very similar in design and analysis, so what could explain these apparently conflicting results from two similar studies conducted just 3 yrs apart.
One possible explanation is the increased use of deleukocyted blood since the ABC study was conducted. Blood transfusions are associated with various risks linked to the white blood cell component of the transfusion, and if this is removed could some of these risks be reduced? Leukoreduction is a process in which the white cells are intentionally reduced in number through centrifuga- tion or filtration. Leukocyte counts can be reduced by Ͼ99%, and the technique is effective in reducing the transmission of cell-associated viruses, especially cytomegalovirus, herpes viruses, and EpsteinBarr virus (34) . Leukoreduction may also reduce parasite and prion transmission, transfusion-related febrile reactions, and transfusion-related acute lung injury. Several randomized controlled studies have evaluated the effects of leukoreduction in various groups of patients (Table  3) , although no randomized controlled trial has compared leukoreduced blood with nonleukoreduced blood in critically ill patients. In a before-after cohort study of 14,786 patients who received RBC transfusions following cardiac surgery or repair of hip fracture, or who required intensive care following a surgical intervention or multiple trauma, transfusion of leukoreduced blood was associated with fewer febrile reactions and reduced posttransfusion antibiotic use (35) . In a meta-analysis of 14 randomized controlled trials comparing standard blood with leukoreduced or autologous blood, Vamvakas (36) reported no consistent effect of leukoreduction on long-term mortality. In another meta-analysis of ten randomized controlled trials, the authors concluded that "patients who were transfused leukoreduced RBCs might benefit from a decrease in postoperative infections" (37) . Many countries have now adopted routine leukoreduction based on its supposed benefits, although it makes blood transfusion more expensive and whether it should be used in all a patients is a matter of ongoing debate (38) . Blood storage is another interesting area of debate. Red blood cells are altered with prolonged storage, with reduced deformability, increased fragility, shortened life span, release of antioxidants, and depleted 2,3-diphosphoglycerate levels, and many of these storage lesions get worse with increased length of storage (39, 40) .
However, what impact if any do these changes have on the ability of the red cells to release oxygen, and are these changes clinically important? An early study by Marik and Sibbald (41) suggested that patients receiving RBCs that had been stored for Ͼ15 days before transfusion developed evidence of splanchnic ischemia, but these results have been challenged by others (22, 23) , and in a small retrospective study of patients with severe sepsis, Purdy et al. (42) reported a correlation between increasing age of transfused RBCs and mortality. Others have also suggested an increased incidence of nosocomial pneumonia (43) and of multiple organ failure (44) in patients receiving stored blood. However, more recently Vamvakas and Carven (45) reported no association between age of RBCs and postoperative morbidity or mortality in patients undergoing coronary artery bypass graft. This whole area clearly needs further study particularly as more and more hospitals are now using leukoreduced blood. Storage duration and white blood cell content likely interact because longer storage duration would be expected to cause greater accumulation of white blood cell-derived cytokines, and any detrimental effects of storage may therefore be reduced in leukoreduced blood (40) . Walsh et al. (23) reported that transfusion of stored leukodepleted red cells to euvolemic, anemic, critically ill patients had no clinically significant adverse effects on gastric tonometry or global indexes of tissue oxygenation.
CONCLUSION
Anemia is common in critically ill patients and carries risks of reduced oxygen carriage and worse outcomes. Transfusions, however, carry their own risks, and the physician must balance the risks of anemia with the risks of transfusion in each patient. Much has changed in blood transfusion practice since Hebert et al.
(1) performed their study comparing a liberal with a restrictive approach to transfusion. Many centers are now transfusing at much lower hemoglobin thresholds than before (4, 5) , and some would even argue that the trend to transfuse at lower hemoglobin concentrations has gone too far and patients may risk being undertransfused (46) . The widespread use of leukoreduction may have had an impact on the risks associated with blood transfusions, and we eagerly await the results of a multiple-center European study by the SOAP collaborative comparing the liberal strategy of maintaining hemoglobin concentrations Ͼ9 g/dL with a restrictive approach to red cell transfusion that maintains hemoglobin concentrations between 7 and 9 g/dL in critically ill patients with euvolemia.
